Polymorphism in microRNA-binding site in HNF1B influences the susceptibility of type 2 diabetes mellitus: a population based case–control study

Naoki Goda1, Haruna Murase1, Nobuhiko Kasezawa3,4, Toshinao Goda2 and Kimiko Yamakawa-Kobayashi1*

Abstract

Background: Recent genome-wide association studies (GWAS) have identified many SNPs associated with type 2 diabetes mellitus (T2DM). However, the functional roles for most of the SNPs have not been elucidated. MicroRNAs (miRNAs) are key regulators of gene expression involved in the development and progression of various diseases including T2DM. In this study, we investigated whether commonly occurring SNPs modulate miRNA-directed regulation of gene expression, and whether such SNPs in miRNA-binding sites are associated with the susceptibility for T2DM.

Methods: Genotypes of eleven 3′ untranslated region (UTR) SNPs of seven susceptibility genes for T2DM were determined in 353 T2DM patients and 448 control subjects. In addition, the interactions of miRNAs with the 3′UTR in the hepatocyte nuclear factor 1β (HNF1B) gene were investigated using luciferase reporter assays.

Results: One 3′UTR SNP (rs2229295) in the HNF1B gene was significantly associated with T2DM, and the frequency of an A allele (rs2229295) in T2DM patients was decreased compared with that in controls. Luciferase reporter assays showed that the SNP (rs2229295) altered the binding of two miRNAs (hsa-miR-214-5p and hsa-miR-550a-5p).

Conclusions: We have detected the interactions of hsa-miR-214-5p/hsa-miR-550a-5p and the 3′UTR SNP of the HNF1B gene by in vitro luciferase reporter assays, and propose that the binding of such miRNAs regulates the expression of the HNF1B gene and the susceptibility of T2DM.

Background

Type 2 diabetes mellitus (T2DM) is a common heterogeneous and complex disease that is characterized by hyperglycemia resulting from impaired pancreatic β-cell function and a decreased action of insulin on target tissues. A combination of multiple genetic and environmental factors is considered to contribute to the pathogenesis of this disease. Patients with T2DM are at greater risk of developing cardiovascular diseases, renal failure, neurological conditions, and retinopathy [1–3].

Recent genome-wide association studies (GWAS) have successfully identified over 65 susceptibility loci associated with T2DM and related metabolic traits [4–6]. GWAS have been a powerful approach to identify single nucleotide polymorphisms (SNPs) associated with disease risk. However, most of the SNPs in susceptibility genes for T2DM identified in previous studies were located within non-translated regions, such as introns, 3′-untranslated regions (3′UTRs), and 5′UTRs. Therefore, functional roles for many of the SNPs in susceptibility genes have not been elucidated.

MicroRNAs (miRNAs) are endogenous noncoding RNAs (19–25 nucleotides in length) that induce the translational repression and degradation of target mRNAs by complementarily binding to their 3′UTR [7]. By silencing their target gene expression, miRNAs are involved in a variety of biological processes, as well as the development and progression of human diseases including cancer and T2DM [8–13]. Previous studies showed that SNPs within or proximal to miRNA-binding sites in target genes have the potential to either create or destroy binding sites, which affects the
efficiency of miRNA binding on target sites. Thus, SNPs in miRNA-binding sites may modulate expression and protein levels of target genes, and ultimately contribute to phenotypic variations, including disease susceptibility and important traits [9–11, 14].

In this study, we investigated whether commonly occurring SNPs modulate miRNA-directed regulation of gene expression, and whether such SNPs in miRNA-binding sites are associated with the susceptibility for T2DM.

Methods

Subjects

The participants recruited for this study were Japanese who underwent a routine medical check-up at a medical center near the University of Shizuoka. We selected men under 65 years of age as subjects in this study. The case subjects with T2DM (n = 353) were diagnosed as T2DM by physicians according to the World Health Organization (WHO) diagnostic criteria for T2DM [15]. Of these, 251 T2DM patients (71.1 %) were under oral medication for diabetes. The control subjects (n = 448) were randomly selected according to the following criteria to exclude persons with potential glucose intolerance: (1) fasting plasma glucose levels were under 100 mg/dL (5.6 mmol/L), and (2) HbA1c levels were under 6.2 %. All subjects provided written informed consent to participate in this study, and the study was approved by the Ethics Committee of the University of Shizuoka (Approval No. 17-1).

After overnight fasting, blood was collected from each subject. The clinical characteristics of the subjects were determined according to the medical check-up protocol (Table 1).

DNA analysis

We first selected 20 risk genes for T2DM, which contains 17 risk genes that had been examined the association for T2DM in our previous study [16], and three risk genes (PPARGC1A, IRS2, and SPRY2) [17–19]. These 20 genes were confirmed the association with T2DM in Asian populations [4, 5]. Next, we searched SNPs in the miRNA-binding sites in the 3′UTR of these 20 T2DM risk genes using three online databases: MirSNP [20, 21], PolymiRTS database 3.0 [22, 23], and miRNASNP [24, 25]. Finally, we selected 11 SNPs with minor allele frequency >0.05 in Japanese in the 3′UTR of seven T2DM susceptible genes (Table 2).

Genomic DNA was isolated from peripheral leukocytes by the phenol extraction method. The genotypes of the SNPs were determined for each subject using the PCR-restriction fragment length polymorphism method.

HNF1B 3′UTR reporter gene construction

Two SNPs (rs2229295 C > A, rs1800929 A > G) lie next to each other in the microRNA binding sites in the 3′UTR of the hepatocyte nuclear factor 1B (HNF1B) gene. The HNF1B 3′UTR (920 bp) was amplified using PrimeSTAR® HS DNA Polymerase (Takara Bio Inc., Otsu, Japan) from the genomic DNA of the homozygote for major alleles of the two SNPs (C for rs2229295, A for rs1800929). The primer sequences are listed in Additional file 1.

The purified PCR product was subcloned into pUC18 vector. We then generated five distinct reporter gene constructs containing sequences as follows: (1) C (rs2229295), A (rs1800929), (2) C (rs2229295), G (rs1800929), (3) A (rs2229295), A (rs1800929), (4) A (rs2229295), G (rs1800929), and (5) T, C (as a reference; Table 1)

|                      | T2DM            | Control         | P-value          |
|----------------------|-----------------|-----------------|------------------|
| **Age (years)**      | 54.4 ± 6.5      | 53.7 ± 5.1      | 0.12             |
| **BMI (kg/m²)**      | 25.0 ± 3.6      | 23.1 ± 2.6      | <0.0001          |
| **Glucose (mg/dl)**  | 155.0 ± 43.2    | 91.8 ± 4.9      | <0.0001          |
| **HbA1c (%)**        | 7.7 ± 1.57      | 5.4 ± 0.34      | <0.0001          |
| **SBP (mmHg)**       | 126.3 ± 15.6    | 120.5 ± 16.2    | <0.0001          |
| **DBP (mmHg)**       | 79.9 ± 11.0     | 76.8 ± 12.0     | 0.0002           |
| **Total-cholesterol (mg/dl)** | 212.5 ± 34.7 | 210.2 ± 31.7 | 0.33          |
| **LDL-cholesterol (mg/dl)** | 130.8 ± 29.9 | 129.5 ± 29.9 | 0.55          |
| **HDL-cholesterol (mg/dl)** | 54.0 ± 15.9 | 58.4 ± 16.4 | 0.0001          |
| **Triglyceride (mg/dl)** | 161.8 ± 145.0 | 136.3 ± 112.8 | 0.0001          |
| **Obesity/Overweight (BMI ≥ 25) (%)** | 45.0 | 23.2 | <0.0001          |
| **Current smoker (%)** | 43.7 | 41.8 | 0.61          |

*Statistical test for glucose and triglyceride levels were caluculated on log-transformed values
P-values between T2DM and control groups were calculated by t-test or χ²-test
Data are expressed as mean ± SD or percentage
randomly selected nucleotide sequence), by site-directed mutagenesis using PrimeSTAR® Mutagenesis Basal Kit (Takara Bio). The primer sequences used in the site-directed mutagenesis are listed in Additional file 1. These inserts were removed by digestion with Smal I and Hind III, and cloned downstream of the luciferase gene in a reporter vector; pMIR-REPORT™ Luciferase (Ambion Inc., Austin, TX, USA). Each construct was sequenced to confirm the sequence and orientation of the insert.

**Table 2** Associations between T2DM and 3’ UTR SNPs of susceptibility genes for T2DM

| Gene   | SNP       | Predicted interacting miRNA | Genotype | T2DM n (%) | Control n (%) | OR (95%CI) | P-value | Power |
|--------|-----------|-----------------------------|----------|------------|---------------|------------|---------|-------|
| SLC30A8| rs11558471| hsa-miR-1205                | AA       | 130 (37.3) | 135 (30.7)    | 1 (Reference) | 0.022   | 0.78  |
|        |           | hsa-miR-1248                | AG       | 168 (48.1) | 229 (52.1)    | 0.78 (0.62–0.96) |        |       |
|        |           | hsa-miR-3074-5p             | GG       | 51 (14.6)  | 76 (17.3)     | 0.60 (0.39–0.93) |        |       |
|        | rs3802178  | hsa-miR-1234-3p             | AA       | 145 (41.6) | 215 (48.4)    | 1 (Reference) | 0.10    | 0.74  |
|        |           |                             | GA       | 169 (48.4) | 187 (42.1)    | 1.21 (0.96–1.51) |        |       |
|        |           |                             | GG       | 35 (10.0)  | 42 (9.5)      | 1.46 (0.93–2.30) |        |       |
|        | rs2466295  | hsa-miR-586                 | TT       | 275 (77.9) | 341 (76.8)    | 1 (Reference) | 0.67    | 0.52  |
|        |           |                             | TC       | 71 (20.1)  | 91 (20.5)     | 0.94 (0.69–1.27) |        |       |
|        |           |                             | CC       | 7 (2.0)    | 12 (2.7)      | 0.88 (0.48–1.60) |        |       |
|        | rs2466293  | hsa-miR-181a-2-3p           | TT       | 95 (27.3)  | 145 (33.2)    | 1 (Reference) | 0.11    | 0.78  |
|        |           | hsa-miR-660-5p              | TC       | 181 (52.0) | 203 (46.5)    | 1.19 (0.96–1.47) |        |       |
|        |           | hsa-miR-888-3p              | CC       | 72 (20.7)  | 89 (20.4)     | 1.41 (0.93–2.15) |        |       |
|        | HNF1B     | rs2229295                   | CC       | 278 (78.7) | 308 (68.8)    | 1 (Reference) | **0.004** | 0.61  |
|        |           | hsa-miR214-5p               | CA       | 66 (18.7)  | 121 (27)      | 0.66 (0.50–0.88) |        |       |
|        |           | hsa-miR550a-5p              | AA       | 9 (2.6)    | 19 (4.2)      | 0.44 (0.25–0.77) |        |       |
|        | rs1800929  | hsa-miR214-5p               | AA       | 238 (67.4) | 285 (63.6)    | 1 (Reference) | 0.071   | 0.65  |
|        |           | hsa-miR550a-3-5p            | AG       | 100 (28.3) | 142 (31.7)    | 0.79 (0.60–1.02) |        |       |
|        |           | hsa-miR1271-3p              | CC       | 15 (4.3)   | 21 (4.7)      | 0.62 (0.37–1.04) |        |       |
|        | CDC123    | rs10951                      | GG       | 169 (53.5) | 249 (60.9)    | 1 (Reference) | 0.027   | 0.65  |
|        |           | hsa-miR-145-5p              | GA       | 134 (42.4) | 147 (35.9)    | 1.36 (1.04–1.79) |        |       |
|        |           | hsa-miR-4712-5p             | AA       | 13 (4.1)   | 13 (3.2)      | 1.86 (1.07–3.22) |        |       |
|        | PPARGC1A  | rs6821591                    | TT       | 180 (55.7) | 200 (48.7)    | 1 (Reference) | 0.13    | 0.73  |
|        |           | hsa-miR-187-3p              | TC       | 120 (37.2) | 180 (43.8)    | 0.83 (0.65–1.06) |        |       |
|        | IRS2      | rs2289047                    | CC       | 23 (7.1)   | 31 (7.5)      | 0.69 (0.42–1.12) |        |       |
|        | UBE2E2    | rs7631705                    | TT       | 155 (47.8) | 165 (42.5)    | 1 (Reference) | 0.018   | 0.76  |
|        |           | hsa-miR-888-3p              | TC       | 143 (44.1) | 170 (43.8)    | 0.75 (0.59–0.95) |        |       |
|        |           | hsa-miR-4526                | CC       | 26 (8.0)   | 53 (13.7)     | 0.57 (0.35–0.91) |        |       |
|        | IRS2      | rs2289047                    | GG       | 103 (29.6) | 141 (32.3)    | 1 (Reference) | 0.22    | 0.78  |
|        |           | hsa-miR-376c-3p             | GT       | 163 (46.8) | 215 (49.3)    | 1.14 (0.92–1.40) |        |       |
|        |           |                                | TT       | 82 (23.6)  | 80 (18.4)     | 1.29 (0.85–1.96) |        |       |
|        | SPRY2     | rs1644394                    | TT       | 199 (57.0) | 255 (58.5)    | 1 (Reference) | 0.77    | 0.69  |
|        |           | hsa-miR-1224-3p             | TG       | 124 (35.5) | 146 (33.5)    | 0.97 (0.77–1.22) |        |       |
|        |           | hsa-miR-1260a               | GG       | 26 (7.5)   | 35 (8.0)      | 0.93 (0.59–1.48) |        |       |

Odd ratios and P-values were adjusted by age and BMI
Statistically significant P-value after Bonferroni correction was indicated in bold
Power to detect association was estimated under current sample size and minor allele frequency, assuming OR = 1.2 and additive effect
Luciferase reporter assay

HEK293 cells (a human embryonic kidney cell line) were cultured in Dulbecco’s Modified Eagle’s medium with 10 % fetal bovine serum. The cells were seeded in 24-well plates 24 h before transfection. When the cells were grown to about 80–90 % confluence, the reporter plasmid (150 ng/well) and miRNA mimics (5 pmol/well) (Bioneer Inc., Daejeon, Korea) were transfected using Lipofectamine 2000 (Invitrogen, Inc., Carlsbad, CA, USA) according to the manufacturer’s instruction. The pBGR-TK vector containing *Renilla reniformis* luciferase (6.5 ng/well) (Promega Inc., Madison, WI, USA) was also co-transfected to standardize transfection efficiency. After 24 h, luciferase activity in cell lysate was measured using the Dual-Luciferase Reporter Assay System (Promega). Three independent transfection experiments were performed in triplicate.

Statistical analyses

The associations of genotypes of the eleven 3’ UTR SNPs in seven T2DM susceptibility genes and T2DM were examined. The genotype specific odds ratios (ORs) with 95 % confidence intervals (CIs) and p-values for T2DM were calculated using logistic regression analysis, adjusting for age and BMI.

In the luciferase reporter assay, the differences in the luciferase activity between four kinds of constructs (CA, CG, AA and AG) were examined by Tukey-Kramer multiple comparisons test. All statistical analyses were performed using the JMP software package (SAS Institute, Cary, NC, USA). The power to detect an association between each SNP and T2DM was estimated under current sample size and minor allele frequency observed in this study using “Quanto” [26], assuming OR = 1.2, α level = 0.05 (one-sided), and additive model.

For association between T2DM and each SNP, \( p < 0.0045 \) (0.05/11) was considered as significant by applying a Bonferroni correction.

Results

We analyzed the relationships between T2DM and genotypes of eleven 3’ UTR SNPs in seven T2DM susceptibility genes that were previously detected by GWAS. The genotype distributions of these 11 SNPs were in Hardy-Weinberg equilibrium \( (P > 0.05) \). Table 2 shows the associations between T2DM and these SNPs. The ORs and \( p \)-values were adjusted for age and BMI in logistic regression analysis. One 3’ UTR SNP (rs2229295) in the *HNF1B* gene was significantly associated with T2DM, and the frequency of CA and AA genotypes of rs2229295 in T2DM patients was decreased compared with that in controls \( (OR = 0.66 \ (95 \% \ CI: 0.50–0.88), \ 0.44 \ (95 \% \ CI: 0.25–0.77), \ respectively) \) (Table 2). These data indicate that the A allele of 3’ UTR SNP (rs2229295) in the *HNF1B* gene can be a protective allele for T2DM. The other ten 3’ UTR SNPs in the susceptibility genes were not associated with T2DM.

To investigate the functional impact of the SNP (rs2229295) in the *HNF1B* gene, we next searched miRNAs whose binding could be affected by the base substitution due to this SNP (rs2229295) using online databases (MirSNP, PolymiRTS, and miRNASNP). We identified four candidate miRNAs whose seed sequences correspond with complementary sequences around the SNP (rs2229295) (Fig. 1). In this region, two SNPs (rs2229295 C > A, rs1800929 A > G) are located next to each other. In addition, the seed sequences of these four miRNA contain complementary sequences to the minor alleles of two SNPs (A for rs2229295, G for rs1800929) of the *HNF1B* gene (Fig. 1).

Next, we tested whether the binding of these four miRNAs to the 3’ UTR of the *HNF1B* gene was affected...
by the two SNPs. We generated four kinds of luciferase reporter constructs and one reference construct as described in Methods (Fig. 2a). The constructs were each co-transfected in parallel with the four predicted candidate miRNA mimics into HEK293 cells, and luciferase activity was compared. When hsa-miR-214-5p or hsa-miR-550a-5p mimics were co-transfected with the reporter construct, significant suppression of luciferase activity was observed in constructs containing AA or AG sequences for the two SNPs (rs2229295, rs1800929) compared with the construct containing CA sequence, which presumably does not bind miRNAs (Fig. 2b). When the other two miRNA mimics (hsa-miR-550a-3-5p, hsa-miR-1271-3p) were co-transfected with each reporter construct, there were no differences in luciferase activity among reporter constructs (Additional file 2). Furthermore, there were no differences in luciferase activities among reporter constructs when they were transfected into HEK293 cells without miRNA mimics (Additional file 3).

These data indicate that the substitution of C > A due to SNP (rs2229295) induces a decrease of luciferase activity. However, A > G substitution due to SNP (rs1800929) did not affect luciferase activity. The results of luciferase reporter assays showed that the SNP (rs2229295) actually alters the binding of two miRNAs (hsa-miR-214-5p and hsa-miR-550a-5p), and A allele carrying constructs were specifically regulated by the two miRNAs, while the adjacent SNP (rs1800929) did not affect the binding of the miRNAs to HNF1B 3’UTR.

Discussion

Previous studies have demonstrated that genetic variations within miRNA-binding sites could modulate gene expression and protein levels, and affect phenotypes or cause disease [8–10]. In this study, we identified an SNP (rs2229295) in the 3’UTR of the HNF1B gene that could affect miRNA binding and that was associated with the risk of T2DM. Two SNPs (rs2229295, rs1800929) lie next to each other in this region. In silico analysis predicted that substitutions C > A in rs2229295 and A > G in rs1800929 create a new potential miRNA-binding site.
in the 3′ UTR of the HNF1B gene (Fig. 1). It was ascertained one SNP (C > A in rs2229295) could affect the binding of two miRNAs (hsa-miR-214-5p, hsa-miR-550a-5p) by luciferase reporter assay. However, the other SNP (rs1800929) and two miRNAs (hsa-miR-550a-3-5p, hsa-miR-1271-3p) did not influence the luciferase activity. Many potential miRNA target sites can be predicted in 3′ UTRs of many genes by in silico analysis. However, the binding of miRNAs and target genes have considerable flexibility and therefore in silico analysis is not sufficient to define 3′ UTR SNPs related to susceptibility of common diseases.

HNF1B is a homeodomain-containing transcription factor expressed in multiple tissues, such as the liver, kidney, pancreas, and genital tract [27, 28]. Mouse studies revealed that HNF1B is a critical regulator of transcriptional network that controls the specification, growth, and differentiation of the embryonic pancreas [29–31]. In humans, mutations in the HNF1B gene were described in a monogenic form of diabetes, namely maturity-onset diabetes of the young type 5 (MODY5) [28, 32–35]. Many patients with MODY5 have impaired insulin secretory responses to glucose and show progressive loss in basal insulin secretion, although they have various other abnormalities such as renal cysts, renal impairment, and genital malformation [28–35].

Some GWAS revealed that several tag SNPs in the HNF1B gene were associated with the susceptibility of T2DM, and such associations were well replicated in many countries [36–38]. However, the SNP (rs 2229295) that was associated with the risk of T2DM in this study was not a tag SNP for the HNF1B gene. There is no report for the association of this SNP (rs 2229295) and T2DM. We could not observe significant linkage disequilibrium (LD) between the SNP (rs 2229295) and a tag SNP (rs7501939) of the HNF1B gene (Additional file 4).

Recently, Kornfeld and colleagues found that obesity-induced overexpression of miR-802 causes glucose intolerance, impairs insulin signaling, and promotes hepatic gluconeogenesis in the liver through direct silencing of HNF1B, and showed an important role for HNF1B in the control of hepatic insulin sensitivity and glucose metabolism in vivo [39].

We have detected the interactions of hsa-miR-214-5p/hsa-miR-550a-5p and the 3′ UTR of the HNF1B gene by in vitro luciferase reporter assays, and our results suggest that binding of hsa-miR-214-5p and hsa-miR-550a-5p may also regulate the expression of the HNF1B gene. Unfortunately, we could not examine the interactions between such miRNAs and the endogenous HNF1B gene. Because the genomic sequence of miRNA binding site of the HNF1B gene in HEK293 cells that we used in this study is C (rs2229295), this sequence does not bind hsa-miR-214-5p and hsa-miR-550a-5p. Furthermore, we have no data as to whether HNF1B mRNA and/or protein levels in vivo are affected by the genotype of the SNP (rs2229295).

The miR214 gene is located in an intronic region of the Dynamin-3 gene on human chromosome 1q24.3, and is expressed in the liver, kidney, pancreas, and osteoblasts involved in the development of pancreas and bone [40, 41]. The miR-550 gene is located in the intronic region of the Znf2 gene on human chromosome 7p14.3, and expressed in multiple cancers including hepatocellular carcinoma [42]. However, there is little information regarding the function and regulation of expression of miR-550 in normal cells and tissues. We need to know how the expressions of hsa-miR-214-5p and hsa-miR-550a-5p are regulated in vivo.

In this study, we found the possibility that the binding of two miRNAs to the 3′ UTR of the HNF1B gene provided the protective effect for T2DM. In most patients with MODY5, the clinical phenotypes may be related to loss of function or dominant-negative mechanisms for HNF1B [28, 32–35]. However, a previous study reported a mutation that showed a gain-of-function phenotype with increased transcript activity of the HNF1B gene [43]. Important roles of HNF1B for complex transcriptional networks in pancreatic β-cells and hepatocytes have been established [35, 44, 45]. There is a possibility that the dysregulated expression of the HNF1B gene due to nucleotide changes within the miRNA-binding site would lead to impaired transcriptional networks related to HNF1B and the differences of susceptibility for T2DM. Further experiments are needed to ascertain roles for hsa-miR-214-5p and hsa-miR-550a-5p and HNF1B-dependent regulation of insulin secretion, glucose metabolism in vivo.

Conclusions

In this study, we found the 3′ UTR SNP (rs2229295) in the HNF1B gene was associated with the susceptibility of T2DM. In addition, luciferase reporter assays indicate that the substitution of C > A due to SNP (rs2229295) induces the binding of hsa-miR-214-5p/hsa-miR-550a-5p to the 3′ UTR of the HNF1B gene.

There is a possibility that the dysregulated expression of the HNF1B gene due to nucleotide changes within miRNA binding site lead the difference of susceptibility for T2DM.

Additional files

Additional file 1: Table S1. PCR primers used for subcloning and introduction of nucleotide changes in 3′UTR of HNF1B. (XLSX 11 kb)

Additional file 2: Figure S1. Effect of miRNA (A: hsa-miR-550a-3-5p, B: hsa-miR-1271-3p) binding to reporter constructs. There was no significant difference in luciferase activities among constructs containing CA, AA, or AG sequences for SNP rs2229295 and rs1800929. Luciferase activities.
relative to reference vector (TC vector) were shown as mean ± S.E. from 3 independent transfection experiments with triplicate assays. The comparisons of luciferase activity among four constructs were using Turkey-Kramer method. (PDF 10 kb)

Additional file 3: Figure S2. Effect of the base substitutions due to SNPs (rs2229295 and rs1800929) to luciferase activity. There was no significant difference in luciferase activity of each reporter construct containing CA, CG, AA, AG sequence, suggesting that the difference in 3UTR sequence due to SNPs (rs2229295 and rs1800929) did not affect the luciferase activity by itself. Luciferase activity was normalized to Renilla luciferase levels. Luciferase activities relative to reference vector (TC vector) were shown as mean ± S.E. from 3 independent transfection experiments with triplicate assays. The comparison of luciferase activity among four constructs were using Turkey-Kramer method. (PDF 7 kb)

Additional file 4: Table S2. The pairwise linkage disequilibrium (LD) values of |D'| (upper) and r² (lower) (XLSX 11 kb)

Abbreviations
GWAS: Genome-wide association studies; SNP: Single nucleotide polymorphism; T2DM: Type 2 diabetes mellitus, miRNA: microRNA; 3’ UTR: 3’ untranslated region; HNF1B: Hepatocyte nuclear factor 1 beta; WHO: World Health Organization; Hba1C: Hemoglobin A1c; PCR: Polymerase chain reaction; ORs: Odds ratios; CI: Confidence intervals; SLC30A8: Solute carrier family 30 (zinc transporter), member 8; CDC123: Cell division cycle 123; PPARG: Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha; UBE2E2: Ubiquitin-conjugating enzyme E2E 2; IRS2: Insulin receptor substrate 2; SPRY2: Sprouty drosophila homolog of 2.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
NG and KY-K designed this study. NG, HM, and KY-K carried out the genetic analysis. NG performed the microRNA binding assays. NK and TG collected study subjects. NG and KY-K drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgments
We are grateful to the subjects for their participation in this study. This study was supported by Grant-in-Aid for Scientific Research (C) 25504007 from MEXT/SPS.

Author details
1Laboratory of Human Genetics, School of Food and Nutritional Sciences, Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka, Shizuoka 422-8526, Japan. 2Laboratory of Nutritional Physiology, School of Food and Nutritional Sciences, Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka, Shizuoka 422-8526, Japan. 3Department of Data Management for Health Evaluation & Promotion, Shizuoka Medical Center, Shizuoka 422-8033, Japan. 4Present address: Fuji iki-iki Hospital, Health Promotion Center, Temma, Fuji-shi, Shizuoka 419-0205, Japan.

Received: 1 May 2015 Accepted: 18 August 2015
Published online: 02 September 2015

References
1. Stumvoll MA, Goldstein BA, van Haften TA. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333–46.
2. O’Rahilly S, Barroso I, Wareham NH. Genetic factors in type 2 diabetes: the end of the beginning? Science. 2005;307:370–3.
3. Ashcroft FA, Rorsman P. Diabetes mellitus and the β cell: the last ten years. Cell. 2012;148:1160–71.
4. Ayub QA, Moutsiouas LA, Chen Y, Panoutsopoulos KA, Colonna VA, Paganini LA, et al. Revisiting the thrifty gene hypothesis via 65 loci associated with susceptibility to type 2 diabetes. Am J Hum Genet. 2014;94:176–85.
5. Hara KA, Shigima NA, Hosoe JA, Kadowaki TA. Genetic architecture of type 2 diabetes. Biochem Biophys Res Commun. 2014;452:213–20.
6. Mahajan AA, Go MA, Zhang WA, Belou JC, Gauton KA, Ferreira TA, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet. 2014;46:234–44.
7. Bartel DA. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;16:281–97.
8. Ersson AA, Petyt EA. MicroRNAs in development and disease. Clin Genet. 2008;74:296–306.
9. Ryan BA, Robles AA, Harris CA. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10:389–402.
10. Bandiera SA, Hatem EA, Lyonnert SA, Henrion-Caude AA. microRNAs in diseases: from candidate to modifier genes. Clin Genet. 2010;77:306–13.
11. Mendell JT, Olson EA. MicroRNAs in stress signaling and human disease. Cell. 2012;148:1172–87.
12. Hamar PA. Role of regulatory micro RNAs in type 2 diabetes mellitus-related inflammation. Nucleic Acid Ther. 2012;22:289–94.
13. Locke JA, da Silva Xavier GA, Davey HA, Rutter GA, Hamies LA. Increased expression of miR-181 in human islets from individuals with type 2 diabetes is associated with reduced glucose-stimulated insulin secretion. Diabetologia. 2014;57:122–8.
14. Liu CA, Rennie WA, Carmack CA, Kanoria SA, Cheng JA, Lu JA, et al. Effects of genetic variation on microRNA target interactions. Nucleic Acids Res. 2014;42:543–52.
15. WHO Diabetes Programme. About diabetes, http://www.who.int/diabetes/action_online/basics/en/index1.html Accessed 27 Apr 2015.
16. Yamakawa-Kobayashi K, Natsumi M, Aoki S, Nakanoto S, Inamori T, Kaezawa N, et al. The combined effect of the T2DM susceptibility genes is an important risk factor for T2DM in non-obese Japanese: a population based case-control study. BMC Med Genet. 2012;13:11.
17. Villegas R, Williams SM, Gao YT, Long J, Shi J, Cai H, et al. Genetic variation in the peroxisome proliferator-activated receptor (PPAR) and peroxisome proliferator-activated receptor gamma co-activator 1 (PGC1) gene families and type 2 diabetes. Ann Hum Genet. 2014;78:23–32.
18. Bodhini D, Radha V, Deepa R, Ghoosh S, Majumder PP, Rao MRS, et al. The G1057D polymorphism of IRS-2 gene and its relationship with obesity in conferring susceptibility to type 2 diabetes in Asian Indians. Int J Obes. 2007;31:97–102.
19. Imamura M, Iwata M, Maegawa H, Watada H, Hirose H, Tanaka Y, et al. Genetic variants at CDC123/CAMK1D and SPRY2 are associated with susceptibility to type 2 diabetes in the Japanese population. Diabetologia. 2011;54:3071–7.
20. Liu CA, Zhang FA, Li TA, Lu MA, Wang LA, Yue WA, et al. MirSNP, a database of polymorphisms altering miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs. BMC Genomics. 2012;13:661.
21. MirSNP: A collection of human SNPs in predicted miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs. BMC Genomics. 2012;13:661.
22. Bhattacharya AA, Ziebarth JA, Cui YA. PolymiRTS Database 3.0: linking polymorphisms in microRNAs and their target sites with human diseases and biological pathways. Nucleic Acids Res. 2014;42:86–91.
23. PolymiRTS Database 3.0. University of Tennessee Health Science Center, TN. 2013. http://compbio.uthsc.edu/miRNSNP/ Accessed 30 Apr 2015.
24. Gong J, Tong Y, Zhang HM, Wang K, Hu T, Shan G, et al. Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat. 2012;33:254–63.
25. miRNASNP: Huazhong University of Science and Technology, China. 2014. http://bioinfo.life.hust.edu.cn/miRNASNP/ Accessed 30 Apr 2015.
26. QUANTO Version 1.2. by Jim Gudderman, Ph.D. and John Morrison, M.S. University of Southern California http://biostats.usc.edu/software.html Accessed 27 July 2015.
27. Cereghini SA. Liver-enriched transcription factors and hepatocyte. FASEB J. 1996;10:267–82.
28. Edghill EA, Bingham CA, Ellard SA, Hattersley AA. Mutations in hepatocyte nuclear factor-1β and their related phenotypes. J Med Genet. 2006;43:894–900.
29. Coffinier CA, Thepot DA, Babinet CA, Yariv MA, Bara JA. Essential role for the homoprotein vHNF1/vHNF1beta in visceral endoderm differentiation. Development. 1999;126:478–94.
30. Maestro MA, Boj SA, Luco RA, Pierreux CA, Cabedo JA, Servitja JA, et al. Hnf6 and Tcf2 (MODYS) are linked in a gene network operating in a precursor cell domain of the embryonic pancreas. Hum Mol Genet. 2003;12:3307–14.
31. Servitja JA, Rierer JA. Transcriptional networks controlling pancreatic development and beta cell function. Diabetologia. 2004;47:597–613.
32. Horikawa YA, Iwasaki NA, Hara MA, Furuta HA, Hinokio YA, Cockburn BA, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2). Nat Genet. 1997;17:384–5.
33. Fajans SA, Bell GA, Polonsky KA. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001;345:971–80.
34. Fajans SA, Bell GA. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011;34:1878–84.
35. Yamagata K. Regulation of pancreatic beta-cell function by the HNF transcription network: lessons from maturity-onset diabetes of the young (MODY). Endocrine J. 2003;50:491–9.
36. Prokopenko IA, McCarthy MA, Lindgren CA. Type 2 diabetes: new genes, new understanding. Trends Genet. 2008;24:613–21.
37. Billings LA, Florez JA. The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci. 2010;1212:59–77.
38. Zhang XA, Qiao HA, Zhao YA, Wang YA, Sun HA, Liu AA, et al. Association of single nucleotide polymorphisms in TCF2 with type 2 diabetes susceptibility in a Han Chinese population. PLoS One. 2012;7, e52938.
39. Kornfeld JA, Baizel CA, Konner AA, Nicholls HA, Vogt MA, Hermanns KA, et al. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature. 2013;494:111–15.
40. Joglekar MV, Parekh VS, Hardikar AA. New pancreas from old: microregulators of pancreas regeneration. Trends Endocrinol Metabol. 2007;18:393–400.
41. Wang X, Guo B, Li Q, Peng J, Yang Z, Wang A, et al. miR-214 targets ATF4 to inhibit bone formation. Nature Med. 2013;19:99–100.
42. Tian Q, Liang L, Ding J, Zha R, Shi H, Wang Q, et al. MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma. PLoS One. 2012;7, e48958.
43. Yoshuuchi I, Yamagata K, Zhu Q, Tamada I, Takahashi Y, Onigata K, et al. Identification of a gain-of-function mutation in the HNF-1beta gene in a Japanese family with MODY. Diabetologia. 2002;45:154–5.
44. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science. 2004;303:1378–81.
45. Kulkarni RN, Kahn CR. Molecular biology. HNFs-linking the liver and pancreatic islets in diabetes. Science. 2004;303:1311–12.